Abstract
Background and objectives White matter hyperintensities (WMHs) are radiological abnormalities indicative of cerebrovascular dysfunction associated with increased risk for cognitive decline and increase in prevalence in older age. However, there are known sex-differences as older females harbour higher WMH burden than males. Some have hypothesized that the increase in this dementia-related risk factor is related to the menopausal transition.
Methods To untangle the effects of age and menopause, we leveraged a large sample from the UK Biobank (n = 10,519) to investigate differences in WMH volumes across the menopausal transition using a strict age-matching procedure.
Results Surprisingly, we find increased WMH volumes in premenopausal women compared to postmenopausal women when simply correcting for age with linear models, but we find no effect in the age-matched sample. Menopause-related characteristics, such as age at menopause or hormone replacement therapy, did not replicate previous literature reporting an association with WMH volumes. Cardiovascular lifestyle variables, such as smoking and blood pressure, were significant predictors of WMH volume in the full sample without age-matching. These effects varied by menopausal status only for days of moderate activity.
Discussion In sum, our findings in a well-powered study suggest that previous reports of menopause-related differences in WMH burden are potentially confounded by age. We further show that the effect of positive lifestyle factors on brain health, as indexed with WMH burden, generally does not change after menopause. Factors other than the menopausal transition are likely at play in explaining the difference in WMH burden between males and females in later life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of The North West Research Ethics Committee gave ethical approval for the UK Biobank, see https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics. The data used in this work was obtained from UK Biobank under application number 45551.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Requests for access to the data used for this study will be considered by the corresponding author.
